Edition:
United States

CytoDyn Inc (CYDY.PK)

CYDY.PK on OTC Markets Group

0.60USD
26 May 2017
Change (% chg)

$0.01 (+1.68%)
Prev Close
$0.59
Open
$0.59
Day's High
$0.60
Day's Low
$0.57
Volume
101,850
Avg. Vol
273,646
52-wk High
$1.49
52-wk Low
$0.46

Latest Key Developments (Source: Significant Developments)

Cytodyn's Pro 140 for treating HIV deemed too broad for orphan drug designation by FDA
Monday, 17 Apr 2017 06:00am EDT 

April 17 (Reuters) - Cytodyn Inc :Potential for Cytodyn's PRO 140 for treating HIV patients deemed too broad for orphan drug designation by the FDA.Cytodyn Inc - application for orphan drug designation not granted by office of orphan products development of U.S. Food and Drug Administration (FDA).  Full Article

CytoDyn files for mixed shelf of up to $100 million
Friday, 26 Aug 2016 05:09pm EDT 

CytoDyn Inc :Files for mixed shelf of up to $100 million - SEC filing.  Full Article

FDA clears CytoDyn for relaxed entry criteria for its ongoing phase 3 trial in HIV-Infected Patients
Monday, 21 Dec 2015 04:01pm EST 

CytoDyn:Says the FDA has allowed a significant change to the entry criteria for patients in the Company's ongoing PRO 140 Phase 3 trial.This change allows the Company to enroll patients with resistance to a single antiretroviral drug, significantly expanding the number of patients available for the study.  Full Article

CytoDyn cleared by FDA to Start Phase 3 of First Injectable Antibody for HIV
Tuesday, 9 Jun 2015 06:29am EDT 

CytoDyn Inc:Says it has initiated its first Phase 3 study for PRO 140, the company's self-injectable antibody for the treatment of HIV.Company's Phase 3 protocol provides for a 25-week study with 300 HIV-positive patients.  Full Article

More From Around the Web

BRIEF-Cytodyn's Pro 140 for treating HIV deemed too broad for orphan drug designation by FDA

* Potential for Cytodyn's PRO 140 for treating HIV patients deemed too broad for orphan drug designation by the FDA